...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis
【24h】

Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis

机译：长期使用那他珠单抗治疗与多发性硬化症患者生活质量的持续改善相关

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Multiple sclerosis (MS) patients experience lower health-related quality of life (HRQoL) than the general population. In clinical trials, natalizumab significantly improved HRQoL and reduced relapse rates and disability progression in patients with relapsing MS. In a 1-year analysis of patients included in the current study, HRQoL improvement occurred within 3 months of natalizumab initiation and continued for 1 year thereafter. However, natalizumab’s long-term efficacy in improving HRQoL has not been studied. Methods: In this longitudinal, observational, single-arm US study, HRQoL and treatment satisfaction were evaluated in MS patients receiving intravenous natalizumab 300?mg every 4 weeks in clinical settings. Patients completed surveys at baseline and every 6 months for 3 years and reported the following measures: Short Form-12 Version 2 (SF-12v2), Multiple Sclerosis Impact Scale (MSIS-29), and Treatment Satisfaction Questionnaire for Medication. Results: In this study, 120 patients completed ≥3 years of natalizumab treatment. Significant HRQoL improvements were evident from baseline to year 3 by increases in SF-12v2 Physical Component Summary (PCS) and Mental Component Summary scores ( P <0.01) and decreases in MSIS-29 physical and psychological scores ( P <0.0001). Patients with less physical disability (baseline Disease Steps [DS] 0–2) had significant improvement from baseline to year 3 in SF-12v2 PCS ( P <0.05) and MSIS-29 physical scores ( P <0.05). Physical HRQoL outcomes in patients with baseline DS 3–6 remained stable over 3 years. Treatment satisfaction increased significantly from baseline to year 1 ( P <0.0001) and was maintained in the following 2 years. Conclusion: Patients reported physical and psychological HRQoL improvements over 3 years of natalizumab treatment, supporting the long-term efficacy of natalizumab in real-world settings. Lower baseline disease activity and earlier treatment were related to better outcomes, indicating the importance of starting natalizumab early in the disease course. Treatment satisfaction increased after natalizumab initiation and remained high over 3 years of treatment.
机译：背景：多发性硬化症（MS）患者的健康相关生活质量（HRQoL）低于一般人群。在临床试验中，那他珠单抗显着改善了复发性MS患者的HRQoL并降低了复发率和残疾进展。在对本研究中的患者进行的为期1年的分析中，HRQoL的改善在那他珠单抗启动后3个月内发生，并在此后持续1年。然而，那他珠单抗改善HRQoL的长期疗效尚未得到研究。方法：在这项纵向，观察性，单臂美国研究中，在临床环境中每4周接受静脉注射那他珠单抗300？mg的MS患者，评估HRQoL和治疗满意度。患者在基线和每6个月进行了为期3年的调查，并报告了以下措施：简短表格12版本2（SF-12v2），多发性硬化症影响量表（MSIS-29）和药物治疗满意度调查表。结果：在这项研究中，有120名患者完成了那他珠单抗治疗≥3年。从基线到第3年，通过SF-12v2身体成分摘要（PCS）和心理成分摘要得分的提高（P <0.01）和MSIS-29身体和心理得分的降低（P <0.0001），HRQoL显着改善。身体残疾较少（基线疾病步骤[DS] 0–2）的患者从基线到3年级时SF-12v2 PCS和MSIS-29身体评分（P <0.05）有显着改善。基线DS 3–6的患者的身体HRQoL结局在3年内保持稳定。从基线到第1年，治疗满意度显着提高（P <0.0001），并在随后的2年中保持。结论：患者报告了那他珠单抗治疗3年后身体和心理的HRQoL改善，支持那他珠单抗在现实环境中的长期疗效。较低的基线疾病活动度和较早的治疗与较好的预后相关，表明在疾病过程中尽早开始那他珠单抗的重要性。接受那他珠单抗治疗后，治疗满意度增加，并且在治疗3年中一直保持较高水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号